An immunotoxin composed of Pseudomonas toxin coupled to an antibody to the human transferrin receptor was evaluated for its effect on ovarian cancer. In the tumor model employed, 60 million human ovarian cancer cells were
unjected into the peritoneal cavity of an immunodeficient nude mouse. By day 5, cancer cells were implanted and growing in small clusters throughout the peritoneal cavity. On days 5-8, 0.3-2 ,ug of immunotoxin was u jected into the peritoneal cavity. Control mice died with malignant ascites at 34-58 days after the implantation of tumor cells, whereas immunotoxintreated mice lived to 100 days or longer. Irrelevant immunotoxins or antibody alone had no antitumor activity. These findings suggest that intraperitoneal injection of immunotoxins may have a role in the treatment of ovarian cancer.
Human ovarian cancer is a disease that remains confined to the peritoneal cavity throughout most of its course. In patients with ovarian cancer, relapse following an initial course of chemotherapy is usually associated with a poor prognosis. Acquired drug resistance often renders the disease refractory to retreatment with the same agent and crossresistant to other agents (1) . Some new strategies to overcome this resistance are directed toward restoring drug sensitivity to the tumor cells by the use of verapamil (2) , which can increase drug accumulation, or buthionine sulfoximine, which decreases intracellular glutathione levels (3).
We have been developing an alternate approach to chemotherapy using immunotoxins (ITs) made from Pseudomonas exotoxin (PE) coupled to antibodies reactive with antigens present on the surface of ovarian cancer cells (4, 5) . (For a review of ITs, see refs. 6 and 7.) We have previously assessed the activity of these ITs in cell culture (4, 5) . We have now begun to utilize a nude mouse model of human ovarian cancer (8) 21 .5 x 600 mm, Bio-Rad). When tested against OVCAR-3 cells in cell culture as described (4), the IT gave 50% inhibition of protein synthesis at a final concentration of 50 ng/ml. Ascites fluid was examined by using phase-contrast microscopy with a Zeiss 1CM-405 inverted microscope and a 40x N.A. 0.85 long working distance oil-phase objective. The histologic appearance of small tumor implants was examined by fixing small portions ofperitoneal wall removed at autopsy from tumor-injected mice at day 5, followed by routine histologic processing using paraffin embedding and hematoxylin/eosin staining.
RESULTS
To evaluate IT activity, 60 million ovarian cancer cells were injected on day 1 and test materials were administered i.p. on days [5] [6] [7] [8] . The delay before initiation of treatment was to allow the establishment of the tumor. To assess the progress of tumor development at the time of treatment, a group of mice was killed on day 5. The peritoneal cavity on day S contained a large number of nonattached tumor cells that could be washed out with saline ( Fig. L) . Histological sections revealed cell clusters attached to the surface of the liver, the serosal surface of the gastrointestinal tract, and the mesentery (Fig. 1B) . Some of these clusters were organized and surrounded by a connective tissue layer and some invasion of lymphatics and lymph nodes was found. The administration of injections of PE-anti-TFR on days [5] [6] [7] [8] increased the survival of tumor-bearing mice compared with controls. The injection of 1 or 2 ,ug increased the median survival time to =100 days, whereas control mice died on or about day 50 (Fig. 3) , The lower panel ofFig. 2 shows a mouse treated with 2 ,g ofPE-anti-TFR that appeared tumor-free on day 99 (see below). Four injections of 0.3 ,g gave enhanced survival, with a median survival time of 78 days. Thus, there was evidence for a dose-dependent response (Fig. 3) .
We IT per day to mice because of their extreme sensitivity to the toxin. Small numbers of cancer cells are often deposited outside the peritoneal cavity along the needle track at the time of injection of the cancer cells and these eventually grow into extraperitoneal tumors. These extraperitoneal tumors were not affected by doses of IT that were active in the peritoneal cavity. The injection of IT into the peritoneal cavity provides a high concentration of IT within and in the vicinity of the peritoneal cavity and even results in killing of tumors implanted in the peritoneal wall. Apparently the concentration outside the peritoneal cavity is not high enough to kill cells lodged outside the cavity.
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DISCUSSION
This paper provides evidence that PE-ITs can achieve a significant antitumor effect in an animal. Other investigators have shown antitumor effects in various animal model systems using ITs made with ricin A chain (12, 13) , diphtheria toxin A chain (14, 15) , pokeweed antiviral protein (16), or saporin (17) . In some ofthese studies, antibody alone wasjust as effective or almost as effective as the IT (13, 14) , suggesting that toxin-independent mechanisms were operating. In the current study, the antibody alone had no effect on tumor growth. In addition, when excess antitransferrin antibody was given with IT, it blocked IT action, establishing that the IT was binding to a specific and saturable binding site.
One potential advantage of ITs employing PE is their high activity. Generally, ITs made with whole toxins are much more active than A chain toxins (5, (18) (19) (20) . This is probably because a portion of the molecule is retained that enables the toxin to penetrate through cell membranes. In other studies, we have found that an IT made using ricin A chain and a different monoclonal antibody to the human TFR (454A12) was active in this ovarian cancer model but required higher doses of IT (30-100 ug per injection) to achieve a similar therapeutic result (unpublished results).
The current study utilized an antibody to the human TFR to carry the toxin to cancer cells. Though much of the efficacy of this tumor-specific antibody-toxin conjugate in a mouse resides in the species-specific nature of the antibody, this system still demonstrates that properly selected tumorspecific ITs can be expected to be therapeutically useful. It remains to be determined whether or not TFR can serve as a target antigen for treatment of human ovarian cancer. TFRs have been detected in a number of normal tissues, including skin, epithelia of the gastrointestinal tract and bladder, kidney, endocrine pancreas, hepatocytes, Kupffer cells, testis, pituitary, and brain capillary endothelium (21, 22) , and in many different kinds of cancer tissue, including ovarian tumors (23, 24) . However, we have identified a number of monoclonal antibodies that react with ovarian cancer cells and a more limited number of normal tissues than the antibody used in this study (ref. 5; unpublished data). In preliminary studies, some of these are active in the nude mouse model (unpublished data).
This study shows an antitumor activity of an IT made with PE in an ovarian cancer model. It demonstrates a positive result in a model system employing large numbers of tumor cells and the model can be used to evaluate the in vivo activity of ITs made from other antibodies reactive with ovarian cancer tissue. Ovarian cancer is often accompanied by ascites containing many cancer cells. The ascites is due to tumor cell invasion and obstruction of regional lymphatics. The injection of ITs directly in the peritoneal cavity ensures that tumor cells in the ascites and those growing superficially are exposed to a high initial concentration of drug. Furthermore, the IT, like other proteins, leaves the peritoneal cavity by the same lymphatics as cancer cells. These considerations, together with the fact that the blockage of lymphatics often seen in patients with ovarian cancer will slow the diffusion of IT to the blood, may help provide a therapeutic activity against human ovarian cancers.
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